The role of autologous peripheral blood progenitor cell (PBPC) transplantation for high-risk stage II/III breast cancer remains controversial. New prognostic indicators defining subsets of patients who may benefit from autologous PBPC transplantation would be clinically useful. The axillary lymph node ratio, defined by the total number of axillary nodes involved with cancer divided by the number of axillary nodes surgically sampled, has been reported to be of potential prognostic importance in transplantation for high-risk, stage II/III breast cancer. We therefore retrospectively reviewed 111 women with high-risk, stage II/III breast cancer with at least four positive axillary lymph nodes undergoing autologous PBPC transplantation from 1991 to June 1999. None of the patients had received prior radiotherapy and all had completed one, and only one, course of at least three cycles of adjuvant chemotherapy. The median number of axillary nodes sampled was 20 (range 6-40) and the median number of positive axillary nodes was 12 (range 4-35). The median node ratio, dividing the number of positive nodes by the number of sampled nodes, was 0.68. Event-free survival was strongly influenced by node ratio. Patients having a node ratio of Ͻ0.7 had a 5-year event-free survival of 68%, vs those with a node ratio of у0.7 with a 5-year event-free survival of 46% (P = 0.03). Forty percent of patients with a high node ratio have relapsed vs 20% with a low node ratio (P = 0.02). Multivariate analysis revealed that positive estrogen receptor status and a node ratio of Ͻ0.7 were independent factors related to better event-free survival (P = 0.0001 and P = 0.004, respectively). We conclude that patients having a node ratio of Ͻ0.7 have a significantly better prognosis following autologous PBPC transplantation than do patients with a ratio у0.7. Bone Marrow Transplantation (2001) 27, 843-846.
The absolute number of surgically sampled axillary lymph nodes that are involved with breast cancer at the time of diagnosis has been known for years to be of significant prognostic importance. Patients with 10 or more axillary nodes involved with tumor have approximately a 70% chance of disease recurrence despite adjuvant chemotherapy and/or radiotherapy; patients with 4-9 involved axillary nodes have approximately a 50% chance of disease recurrence. [1] [2] [3] [4] Over the past decade, numerous phase II clinical trials were performed utilizing autologous peripheral blood progenitor cells (PBPC) transplantation for such high-risk, stage II/III breast cancer patients. Data from these phase II trials suggested that 60-70% chance of patients with high-risk stage II/III breast cancer might be rendered disease-free with autologous transplantation. [5] [6] [7] [8] [9] [10] Preliminary results, however, of prospective randomized trials comparing autologous transplantation to less intensive chemotherapy have not shown a significant difference in overall survival at the time of data analysis. 11, 12 One trial did show that transplantation was associated with a decreased relapse rate; however, this had not translated into improved survival at the time of data analysis.
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Many variables have long been shown to be of prognostic importance in patients with stage II/III breast cancer treated with conventional therapy. Improved prognostic parameters that might be defined concerning autologous transplantation results would be similarly useful. It would be of great clinical value predicting which patients might have an improved outcome with autologous transplantation, and which patients would be less likely to have a positive clinical outcome. A recent report has suggested that the axillary node ratio, defined as the number of axillary nodes involved with breast cancer divided by the absolute number of axillary nodes sampled, is an independent prognostic feature concerning transplantation outcome for this patient population. 13 We report a retrospective review of 111 women with high-risk stage II/III breast cancer with at least four positive axillary nodes undergoing autologous PBPC transplantation from 1991 to June 1999.
Materials and methods
We retrospectively reviewed 111 women with stage II/III breast cancer undergoing autologous PBPC transplantation from 1991 to June 1999. All patients had at least four posi-tive axillary nodes involved with breast cancer. None of the patients received prior radiotherapy and all had completed one, and only one, course of at least three cycles of adjuvant chemotherapy. Patient characteristics are shown in Table 1 .
PBPC collection and processing
All patients received cytokines alone for PBPC collection, the majority receiving G-CSF (filgrastim) 10 g/kg/day subcutaneously with PBPC collection beginning on the 5th day of filgrastim administration. Patients were pheresed for 3-5 days, with a minimum yield of CD34 + cells of 2.0 × 10 6 CD34 + /kg. PBPC collection was performed on a COBE Spectra leukapheresis machine (COBE, Denver, CO, USA).
Transplant protocol
Three different preparative regimens were used for highdose chemotherapy: Cyclophosphamide 1500 mg/m × one dose; and busulfan 1 mg/kg every 6 h for 4 days (total 16 doses) and cyclophosphamide 60 mg/kg daily for 2 days (11%). G-CSF (filgrastim) was given at a dose of 480 g/day intravenously beginning 5 days after the infusion of PBPCs. Filgrastim was then discontinued after patients received 1.0 × 10 9 neutrophils/mm 2 on 2 consecutive days.
Supportive care
Patients received prophylactic antibiotics consisting of oral acyclovir and ciprofloxacin. Low-dose amphotericin (0.2 mg/kg) was given the day after PBPC infusion. Patients experiencing persistent fevers had their antibiotic coverage broadened. Blood cell transfusions were given to maintain a hemoglobin of greater than 9.0 g/dl, platelet transfusions were given for platelet counts of Ͻ10 9 /l. 
Statistical analysis
Survival and event-free survival were calculated using the Kaplan-Meier method. The curves for the node ratio groups were compared using the log-rank test. Multivariable analysis was done using the Cox proportional hazards model with stepwise selection. An alpha level of 0.05 was considered to be statistically significant.
Results
All patients completed the high-dose chemotherapy preparative regimen. Engraftment was rapid, with a median of 10 days to reach a neutrophil count of 0.5 × 10 9 /mm 2 , and 12 days to a platelet count of 20 × 10 9 /l. Median follow-up of survivors is 3 years. Event-free survival was significantly influenced by a lymph node ratio of Ͻ0.7, as shown in Figure 1 . Sixty-one patients with a lymph node ratio of Ͻ0.7 had a 3-year event-free survival of 78%, vs 58% for patients with a node ratio of у0.7, and patients with a low node ratio had a 5-year event-free survival of 68%, vs 46% for those patients with a node ratio of у0.7 (P = 0.03). There was a trend of improved 3-year overall survival (OS) in the low node ratio group: 3 year OS was 86% vs 73%, P = 0.2. Eighty percent of patients remain alive; 22 have died, 21 due to relapse and one due to pulmonary toxicity. 63% of patients with a lymph node ratio у0.7 have relapsed vs 38% with a lymph node ratio of Ͻ0.7 (P = 0.02).
Multivariate analysis, testing stage (2 vs 3), age (Ͻ35, 35-44, 45-54, у55) the absolute number of positive lymph nodes, the node ratio (Ͻ0.7 vs у0.7) and estrogen receptor status was run for survival and event-free survival. Risk factors for a more favorable event-free survival were positive estrogen receptor status (P = 0.0001), and a lymph node ratio Ͻ0.7 (P = 0.004).
Positive estrogen receptors were a favorable variable for overall survival (P = 0.005); a low node ratio was marginally significant with respect to survival (P = 0.07).
Discussion
Abundant literature exists describing prognostic factors for stage II/III breast cancer treated with conventional therapy. The absolute number of involved axillary nodes at the time of surgery has long been known to be of major prognostic importance. [1] [2] [3] [4] Analysis of the lymph node ratio, however, has not been routinely performed as a separate prognostic variable. Other variables known to be of prognostic importance include tumor size, histologic grade, oxygen receptor and progesterone receptor status, Her-2/neu overexpression, and others. [14] [15] [16] [17] [18] Many phase 2 trials have shown the potential therapeutic efficacy of high-dose chemotherapy in autologous PBPC transplantation for high-risk stage II/III breast cancer. [5] [6] [7] [8] [9] [10] 'High-risk' is generally defined as у10 involved axillary nodes, although data exist showing efficacy of PBPC transplantation in women with 4-9 axillary nodes involved. However, among these many reports, only one describes a multivariate analysis of prognostic factors influencing survival. Somlo et al 5 found that progesterone receptor positivity was associated with improved overall survival and relapse-free survival. The axillary lymph node ratio was not investigated in this trial.
Nieto et al 13 recently reported a retrospective review of 176 patients enrolled in clinical trials of high-dose chemotherapy for high-risk primary breast cancer, and analyzed 23 potential variables for relapse. The axillary lymph node ratio, tumor size, and combined estrogen receptor (ER)/progesterone receptor (PR) status were independent predictors for relapse-free survival. When ER and PR were analyzed separately, neither one had independent value, in contrast with a combined ER/PR status. The study reported that patients with a node ratio of у0.8 had a significantly worse survival than those with a node ratio of Ͻ0.8 (P = 0.0002).
Our retrospective review of 111 high-risk primary breast cancer patients confirmed the importance of a lymph node ratio; we also found that estrogen receptor positivity was an independent favorable prognostic feature. We found a node ratio of 0.7 was highly discriminative in terms of segregating a favorable group of patients vs a less favorable group of patients.
Despite the fact that several authors have shown the importance of dose intensity in the treatment of breast cancer, [19] [20] [21] and despite positive phase II data of high-dose chemotherapy with autologous PBPC transplantation for high-risk stage II/III breast cancer, controversy continues to exist concerning the utility of this therapeutic approach. Preliminary results presented from prospective randomized trials have yet to show a clear survival advantage in patients treated with autologous transplantation, although one report did show decreased relapse rates. Mature data from prospective randomized trials will undoubtedly be of great importance in defining the role of autologous transplantation for high-risk primary breast cancer. Additionally, however, defining patient subsets that may benefit from this treatment approach, as well as patient subsets that may not, is of paramount importance. We believe the axillary lymph node ratio defines an important prognostic variable for patients treated with autologous transplantation, and believe that the axillary lymph node ratio should be incorporated
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